Exploring 7 16 2018 Session 2 Rimm
Let's dive into the details surrounding 7 16 2018 Session 2 Rimm.
- Limits of Monotherapy, and the State of PD-1 and PD-L1 Combination Therapies in Clinical Trials - Roy Herbst, Yale Cancer ...
- Strategies for Incorporating Biomarkers in Clinical Trials for PD-1/PD-L1 Combination Therapies - Lisa Butterfield, University of ...
- More to come August 27th.
In-Depth Information on 7 16 2018 Session 2 Rimm
Session 2 Panelists discuss, and field questions from the audience. Chris Boshoff, Pfizer. Session
That wraps up our extensive overview of 7 16 2018 Session 2 Rimm.
